<DOC>
	<DOCNO>NCT02100839</DOCNO>
	<brief_summary>The purpose first part study determine safety tolerability single dose AEM-28 , apolipoprotein E mimetic , subject high total cholesterol otherwise healthy subject . The pharmacokinetics pharmacodynamics AEM-28 also evaluate . The second part study multiple ascend dose evaluation AEM-28 patient refractory hypercholesterolemia . AEM-28 demonstrate significant lipid lowering activity positive effect artery wall . AEM-28 develop treatment homozygous familial hypercholesterolemia .</brief_summary>
	<brief_title>Safety Study AEM-28 Treat Refractory Hypercholesterolemia</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipoproteinemias</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<criteria>Single Ascending Dose ( SAD ) Study : Male female nonsmoker , ≥18 ≤55 year age , BMI &gt; 18.5 &lt; 32.0 kg/m² Total cholesterol great equal 5.0 mmol/L ( ≥194 mg/dL ) screen Multiple Ascending Dose ( MAD ) Study : Male female nonsmoker , ≥18 ≤75 year age , BMI &gt; 18.5 &lt; 35.0 kg/m² Diagnosis refractory hypercholesterolemia LDL cholesterol level &gt; 2.5 mmol/L ( 97 mg/mL ) screening . On stable lipid lower therapy ≥ 8 week On stable diet ≥ 12 week . SAD Study : Any clinically significant abnormality abnormal laboratory test result find medical screening positive test hepatitis B , hepatitis C , HIV find medical screening . History allergic reaction diphenhydramine , ranitidine , methylprednisone related drug , history significant allergic hypersensitivity reaction ( e.g . angioedema ) substance . MAD Study : Significant health problem within 6 month prior screen , opinion Medical SubInvestigator would prevent subject participate study , include limited : unstable coronary heart disease ; transient ischemic attack ; stroke ; revascularization procedure ; uncontrolled hyperthyroidism ; coagulation disorder ; peptic ulcer GI bleeding ; significant disease central nervous system ; liver renal disease . History allergic reaction diphenhydramine , ranitidine , methylprednisone related drug , history significant allergic hypersensitivity reaction ( e.g . angioedema ) substance .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>hypercholesterolemia</keyword>
	<keyword>apolipoprotein E</keyword>
	<keyword>First Human</keyword>
	<keyword>Apolipoprotein E ( ApoE )</keyword>
	<keyword>Apolipoprotein E Mimetic ( AEM )</keyword>
</DOC>